• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

S2Medical

0.01 SEK

+3.70 %

Less than 1K followers

S2M

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+3.70 %
-20.00 %
-44.55 %
-47.66 %
-47.17 %
-71.28 %
-95.93 %
-99.56 %
-99.84 %

S2Medical operates in the medical technology sector. The company is focused on research and development of various wound healing products. Various products offered include cellulose-based materials and dressings for the healing of burns and chronic wounds. The products are sold under various brands, mainly at a European level. S2Medical was founded in 2013 and is headquartered in Linköping.

Read more
Market cap
5.25M SEK
Turnover
4K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
21.8.
2026

Interim report Q2'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release6/20/2024, 8:32 AM

S2Medical AB: Epiprotect® Demonstrates Significantly Lower Infection Risk in Major Pediatric Study

S2Medical
Regulatory press release11/6/2023, 3:09 PM

S2Medical AB (publ) Signs Exclusive Distribution Agreement with Provas Medical Ltd for the Turkish Market

S2Medical
Regulatory press release8/25/2023, 1:30 PM

S2Medical AB: INTERIM REPORT APRIL - JUNE 2023

S2Medical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release7/5/2023, 6:45 AM

S2Medical AB (publ) announces final outcome in the company's rights issue

S2Medical
Regulatory press release7/4/2023, 8:21 AM

S2Medical AB Secures New Loan Agreement and Aims to be Debt-Free by July 2024

S2Medical
Regulatory press release7/3/2023, 4:26 PM

S2Medical AB: S2Medical (publ) announces preliminary outcome in the company's rights issue

S2Medical
Regulatory press release6/16/2023, 11:45 AM

S2Medical AB (publ) publishes a prospectus regarding the rights issue

S2Medical
Regulatory press release6/8/2023, 3:15 PM

S2Medical AB (publ) signs a manufacturing agreement with a distributor in Saudi Arabia

S2Medical
Regulatory press release5/31/2023, 5:00 PM

S2Medical AB: Interim Report January - March 2023

S2Medical
Regulatory press release5/17/2023, 11:33 AM

S2Medical AB (publ) signs a distribution agreement for the Iranian market

S2Medical
Regulatory press release5/16/2023, 2:45 PM

S2Medical AB: S2Medical wins procurement for wound healing items in the Västra Götaland region

S2Medical
Regulatory press release5/10/2023, 9:34 AM

S2Medical AB: Postponing of publication of the quarterly report for the period January to March 2023

S2Medical
Regulatory press release4/24/2023, 3:09 PM

S2Medical AB: Postponement of publication of annual report

S2Medical
Regulatory press release4/21/2023, 1:37 PM

S2Medical AB: S2Medical wins procurement for wound healing items in the United Arab Emirates worth approximately SEK 3.4 million

S2Medical
Regulatory press release4/13/2023, 9:32 AM

S2Medical AB (publ) signs a distributor agreement in the United Arab Emirates and delivers a record order of the skin substitute Epiprotect worth about SEK 2 million

S2Medical
Regulatory press release3/28/2023, 2:36 PM

S2Medical AB: S2Medical implements a strategic change to reach profitability faster

S2Medical
Regulatory press release3/3/2023, 11:39 AM

S2Medical AB: S2Medical wins procurement for wound healing equipment in Region Halland

S2Medical
Regulatory press release2/22/2023, 2:45 PM

Year-end report January - December 2022 S2Medical AB (publ)

S2Medical
Regulatory press release2/16/2023, 4:44 PM

S2Medical AB: Postponing of publication of the year-end report

S2Medical
Regulatory press release1/2/2023, 4:15 PM

S2Medical AB: Positive outcome when S2Medicals antimicrobial peptides were tested against the multi resistant bacteria that by WHO have been defined as a global health threat

S2Medical